Erythritol and Allulose: The Sugar Alcohols and Rare Sugars: Heart Signals and Safety

The jar sits next to the espresso machine at a friend’s house, white crystals in a glass canister labeled in marker: “the good sugar.” It is allulose. Two years ago it would have been erythritol, until a run of heart headlines sent shoppers hunting for the next thing. As of early 2026, that hunt has made allulose one of the fastest-rising sweetener searches, helped along by social media videos calling it “natural Ozempic” because of how it behaves in animal studies.

Both stories deserve a slower read than a 30-second clip allows. The erythritol concern comes from a 2023 study in Nature Medicine and a 2024 follow-up that measured how blood platelets responded after volunteers drank the sweetener. The allulose enthusiasm rests largely on rodent data and a handful of small human trials.

What follows is an attempt to separate what is measured from what is marketed, and to say plainly how strong each piece of evidence is.

What is allulose, and why is everyone suddenly asking about it?

Allulose, also called D-psicose, is a monosaccharide, meaning a single sugar unit like glucose or fructose. It occurs naturally in tiny amounts in figs, raisins, jackfruit, wheat and maple syrup, which is why it is grouped with the “rare sugars.” Commercial allulose is made by enzymatically converting fructose from corn or beet sugar into its mirror-image cousin.

Chemically it is nearly identical to fructose, differing only in the orientation of one hydroxyl group at the third carbon. That small twist matters enormously. Human digestive enzymes and cellular metabolism largely ignore allulose, so it passes through the body without being burned for energy. Roughly 70 percent is absorbed in the small intestine and leaves unchanged in the urine within a day; the remainder travels to the colon.

The result is a crystal that looks like sugar, dissolves like sugar, browns in the oven like sugar, and delivers about 70 percent of sugar’s sweetness with roughly one-tenth of the calories. The US Food and Drug Administration has accepted multiple Generally Recognized as Safe (GRAS) notices for allulose since 2012, and in 2019 issued guidance allowing manufacturers to leave it out of the “total sugars” and “added sugars” lines on the Nutrition Facts label, while still counting it toward total carbohydrate.

Search interest climbed for two reasons. First, the erythritol heart studies pushed keto and low-carb shoppers toward an alternative with bulk and baking properties. Second, a wave of videos claimed allulose triggers the same gut hormone that semaglutide medications mimic. One of those claims has a real mechanistic basis in animals. Neither has been tested in the kind of large, long human trial that would let anyone call allulose “proven.”

What is erythritol, and how does it differ from allulose?

Erythritol is a sugar alcohol, or polyol: a carbohydrate whose structure resembles both a sugar and an alcohol, though it contains no ethanol and will not intoxicate anyone. Xylitol, sorbitol and maltitol are its better-known relatives. Erythritol is found in trace amounts in pears, grapes, melons and fermented foods, and the human body manufactures a little of it through a metabolic route called the pentose phosphate pathway. Commercial supplies come from fermenting glucose with yeast.

Roughly 90 percent of swallowed erythritol is absorbed in the small intestine and excreted unchanged in urine within about 24 hours. Because so little reaches the colon, it causes far less gas and diarrhea than sorbitol or maltitol, which is why it became the bulking agent in most “stevia” and “monk fruit” blends sold in bags. Erythritol supplies about 0.24 calories per gram, is 60 to 80 percent as sweet as sugar, and produces a noticeable cooling sensation on the tongue.

The practical differences from allulose show up in the kitchen and in the body:

• Allulose caramelizes and browns; erythritol does not, and it tends to recrystallize into a gritty texture when baked goods cool.
• Allulose is a true sugar that the body cannot use; erythritol is a polyol the body barely metabolizes.
• Both leave largely through the kidneys, but allulose leaves a larger share for gut bacteria to encounter.
• Erythritol has decades of use and extensive toxicology; allulose has a shorter commercial history and is not yet authorized in the European Union.

On paper they look like near-substitutes. The safety questions around each, however, come from completely different directions.

What changed recently: the studies behind the erythritol heart headlines

The timeline matters because it explains the migration from one sweetener to the other.

In February 2023, researchers published a multi-part study in Nature Medicine. They began by screening blood samples from more than 1,100 people being evaluated for heart disease, looking for chemicals associated with future heart attack, stroke or death over three years. Erythritol stood out. They then confirmed the association in two more cohorts totaling more than 2,900 people in the United States and Europe; participants with erythritol levels in the top quarter had roughly double the risk of a major cardiovascular event compared with the bottom quarter.

The same paper added laboratory work. Erythritol at concentrations seen in the blood after a sweetened drink made human platelets more likely to clump in test tubes, and it sped up clot formation in mice. Finally, eight healthy volunteers drank an erythritol-sweetened beverage: blood levels rose more than a thousand-fold and stayed elevated above the platelet-activating threshold for two to three days.

In August 2024, the same group published a follow-up in Arteriosclerosis, Thrombosis, and Vascular Biology. Twenty healthy adults consumed either erythritol or glucose in a comparable serving. Erythritol raised platelet reactivity measures; glucose did not.

Then, in mid-2025, a laboratory study in the Journal of Applied Physiology exposed human brain microvascular cells to erythritol and reported increased oxidative stress, less nitric oxide (a molecule that relaxes blood vessels) and more of the constricting molecule endothelin-1. This was a cell-culture experiment, not a human trial.

Around the same period, a WHO guideline from May 2023 advised against relying on non-sugar sweeteners for weight control, based on low-certainty evidence, while explicitly excluding sugar alcohols from its scope. The cumulative effect was a public looking for something new to put in the canister.

What the evidence actually says about allulose and erythritol, graded

Evidence comes in tiers. Randomized controlled trials, where people are assigned by chance to one intervention or another, sit at the top for cause-and-effect questions. Observational cohorts can show associations but cannot rule out that sicker people simply have more of a substance in their blood. Animal and cell studies generate hypotheses. Expert opinion fills the gaps.

Erythritol and cardiovascular events: observational, moderate in size, consistent across three cohorts, but confounded. The body makes its own erythritol, and production rises with obesity, insulin resistance and metabolic stress, exactly the conditions that raise heart risk. The studies could not distinguish dietary erythritol from internally produced erythritol.

Erythritol and platelet reactivity: small randomized crossover experiments in healthy volunteers, plus in-vitro work. These show a plausible mechanism. They do not show that anyone had a clot.

Erythritol long-term safety: decades of toxicology and GRAS review found no harm at typical intakes. No randomized trial has followed erythritol users for cardiovascular outcomes over years. That trial does not exist yet.

Allulose and blood glucose: several small randomized trials, mostly in Japan and Korea, lasting a few hours to 12 weeks, in healthy people and people with type 2 diabetes. They consistently show a smaller post-meal glucose rise when allulose replaces sugar or is eaten alongside carbohydrate. Sample sizes are typically under 100.

Allulose and weight or body fat: one 12-week randomized trial in adults reported modest reductions in body-fat percentage. Single small study, not replicated at scale.

Allulose and GLP-1: rodent studies only, for the hormone effect. Human data are limited to a few small trials measuring glucose, not weight loss driven by appetite hormones.

The honest summary: a mechanistic warning about erythritol that warrants caution and more research, and a promising but thin file on allulose.

How does allulose affect blood sugar and insulin?

This is where allulose has its strongest human evidence, so it is worth being precise about what “strongest” means.

Because allulose is barely metabolized, eating it on its own produces essentially no rise in blood glucose or insulin. Small crossover trials confirm that flat line in both healthy adults and adults with type 2 diabetes. That much is unsurprising for a sugar the body cannot use.

The more interesting finding is what happens when allulose is consumed together with ordinary carbohydrate. In several Japanese trials, adding allulose to a meal containing starch or sugar reduced the peak blood glucose afterward compared with the same meal without it. The proposed mechanisms include:

• Inhibition of intestinal enzymes that break disaccharides into absorbable single sugars, slowing glucose entry into the blood.
• Increased liver uptake of glucose through activation of glucokinase, an enzyme that traps glucose inside liver cells.
• Possible stimulation of gut hormones that slow stomach emptying, shown clearly in rodents and only tentatively in people.

The effect size is modest and the trials are short. None was designed to test whether allulose lowers HbA1c, the three-month blood sugar average that clinicians actually track, over years. None examined complications such as eye or kidney disease.

For someone living with diabetes, the practical translation is narrow: swapping sugar for allulose in a coffee or a dessert removes the glucose spike that the sugar would have caused. That is a real benefit of subtraction. Whether allulose adds anything beyond removing sugar is not established.

Anyone using insulin or medications that lower blood glucose should not adjust those medicines based on a sweetener change. The prescribing clinician is the right person to interpret glucose readings after any dietary shift.

Is allulose like Ozempic? The GLP-1 claim examined

The comparison spread because of one hormone. GLP-1, or glucagon-like peptide-1, is released by cells in the gut after eating; it tells the pancreas to release insulin, slows stomach emptying and signals fullness to the brain. Semaglutide, sold under brand names including Ozempic and Wegovy, is a synthetic molecule that mimics GLP-1 and resists breakdown, so its effect lasts about a week rather than the natural hormone’s few minutes.

Rodent studies have found that allulose in the gut stimulates GLP-1 release, and in some experiments that release helped explain reduced food intake and improved glucose handling in the animals. That is genuinely interesting biology, and it is the seed of the viral claim.

The gap between that seed and a semaglutide comparison is enormous:

• Natural GLP-1, whatever triggers it, is degraded within minutes. A medication engineered to last days operates on a completely different timescale.
• Many ordinary foods raise GLP-1 briefly: protein, fiber, fat and even sugar itself. A brief rise after a meal is normal physiology, not a pharmacological effect.
• Human trials of allulose have measured blood glucose and, in one case, body fat. None has demonstrated appetite suppression or weight loss on the scale seen in medication trials, where participants lost roughly 15 percent of body weight over 68 weeks.
• Semaglutide’s outcomes rest on randomized trials in tens of thousands of participants. Allulose’s rest on dozens.

Calling allulose “natural Ozempic” is a category error. It compares a food ingredient that nudges a hormone for minutes with a prescription medicine that reshapes it for a week. Anyone considering GLP-1 medication for weight or diabetes should discuss that with their treating clinician; a sweetener is not a substitute, and no one should change or stop a prescribed medicine based on sweetener claims.

What is the downside of allulose? Digestive effects and tolerance

Ask a physician who works in a diabetes clinic what patients report about allulose and the answer arrives quickly: the bathroom.

About 30 percent of allulose escapes absorption in the small intestine and reaches the colon. There it does two things. It draws water into the bowel by osmosis, the same mechanism that makes prunes effective. And, unlike erythritol, some of it is fermented by gut bacteria, producing gas. The predictable results are bloating, cramping, rumbling and, at higher intakes, loose stools or diarrhea.

Tolerance studies in healthy adults have identified thresholds above which symptoms become common, and those thresholds are lower when allulose is consumed all at once, on an empty stomach or in liquid form. Spreading intake across the day and pairing it with food reduces complaints. People with irritable bowel syndrome, a functional gut disorder marked by pain and altered bowel habits, tend to react at lower amounts than others.

Beyond the gut, the documented downsides are few but worth naming:

• Limited long-term data. Commercial use is barely a decade old, so there is no cohort followed for 20 years.
• Regulatory divergence. The European Union has not authorized allulose; the United States, Japan, South Korea and several other countries have.
• Label confusion. Because allulose is excluded from “added sugars” on US labels, a product can read “0g added sugar” while containing substantial carbohydrate by weight. Reading the total carbohydrate line, not just the sugar line, avoids surprises.
• Sweet-taste habituation. Expert opinion, not trial data, suggests that keeping the palate accustomed to intense sweetness may make less-sweet whole foods less appealing. This is plausible and unproven.

No serious organ toxicity has appeared in animal studies or GRAS reviews at realistic intakes. The honest downside is uncomfortable, not dangerous, for most people.

Is allulose safe for kidneys?

The question arises for a logical reason: most absorbed allulose exits the body through the kidneys, unchanged, within about 24 hours. If the kidneys are the exit door, do they pay a price for opening it so often?

What is known comes from three sources. Animal toxicology studies that fed rats allulose for months found no kidney injury at intakes far above what a person would consume; some very high-dose studies reported changes in organ weights that regulators judged not toxicologically meaningful. Human trials lasting up to 12 weeks tracked standard kidney markers such as creatinine and found no adverse change. And the GRAS reviews that examined this data concluded that renal excretion of an inert sugar is not a hazard in healthy people.

What is not known is more important for some readers. No trial has enrolled people with chronic kidney disease, a condition in which filtering capacity is already reduced. When the kidneys work at, say, 30 percent of normal, a compound that depends on renal clearance can linger longer in the blood. For a sugar the body does not metabolize, longer circulation is not obviously harmful, but “not obviously harmful” is not the same as “tested.”

Similar reasoning applies to erythritol, which is also cleared mainly by the kidneys. Studies have noted higher circulating erythritol in people with impaired kidney function, which adds another layer of confounding to the cardiovascular cohorts described earlier.

For someone with healthy kidneys, the evidence supports the view that allulose poses no kidney hazard at food-level intakes. For someone with kidney disease, on dialysis, or taking medicines that affect renal function, the sensible route is to ask the nephrology team before making allulose a daily habit. That team can weigh the individual’s filtration rate and other medications; no article can.

Erythritol, platelets and the heart: what a "signal" really means

In research language, a signal is a finding that points somewhere without proving arrival. The erythritol story is a textbook signal, and understanding why it is not yet proof helps in deciding what to do about it.

Platelets are the small cell fragments that plug leaks in blood vessels. When they become too eager to clump, the risk of clots in coronary or brain arteries rises. The 2023 and 2024 volunteer experiments showed that after an erythritol drink, platelets responded more vigorously to clotting triggers in the laboratory, and that this heightened responsiveness persisted while blood levels stayed high. That is a measurable, reproducible physiological change.

Three things separate that change from a demonstrated harm:

• Surrogate versus outcome. Platelet reactivity in a test tube is a surrogate marker. The outcome that matters is a heart attack or stroke. Many surrogates fail to translate.
• Reverse causation in the cohorts. The people with the highest erythritol levels also had the most diabetes, obesity and kidney impairment, all of which increase the body’s own erythritol production and independently raise heart risk. Statistical adjustment reduces but cannot eliminate this problem.
• Dose realism. The volunteer studies used a serving comparable to a single sugar-free dessert or beverage, so the exposure was realistic. What is missing is what happens with daily use over years, and whether the platelet effect fades or accumulates.

The appropriate response to a signal of this kind is neither dismissal nor alarm. It is what several cardiology and nutrition experts have said in plain terms: people already at elevated cardiovascular risk have reasonable grounds to limit erythritol until better data arrive, while healthy people consuming it occasionally have little reason to panic. That framing is expert opinion built on mechanistic and observational evidence, and it is the most anyone can honestly offer today.

Allulose vs erythritol vs stevia vs sugar: a side-by-side comparison

Numbers are easier to weigh in a row than scattered through paragraphs. The table below summarizes what is reasonably established for four common sweeteners; where evidence is thin, it says so.

Feature	Table sugar (sucrose)	Allulose	Erythritol	Stevia (steviol glycosides)
Type	Disaccharide	Rare monosaccharide	Sugar alcohol	Plant-derived high-intensity sweetener
Sweetness vs sugar	100%	About 70%	60–80%	200–400 times
Calories per gram	4	About 0.4	About 0.24 (labeled 0)	Negligible
Blood glucose response	Raises	Flat; may blunt rise from other carbs (small RCTs)	Flat	Flat
Main route out of body	Metabolized	About 70% via urine; rest to colon	About 90% via urine	Liver and gut metabolism
Digestive tolerance	Good	Bloating, loose stools at higher intake	Best-tolerated polyol; rare upset	Good (blends often contain erythritol)
Bakes and browns	Yes	Yes, browns faster	No; may recrystallize	No bulk; needs a filler
Cardiovascular signal	Excess intake linked to heart disease (observational, large)	None reported; short trials only	Platelet reactivity and event association (2023–2024)	None established
Regulatory status	Universal	GRAS in US; not authorized in EU	Approved widely, including EU	Approved widely

Two observations follow. First, the one sweetener in the table with the largest and most consistent body of evidence for harm is ordinary sugar in excess; that context is easy to lose in a debate about substitutes. Second, “approved” and “studied for decades” are not synonyms. Erythritol has both and still produced a surprise. Allulose has one and is newer. Neither fact settles which crystal belongs in the canister; it depends on what the person filling it needs.

Which is better, stevia or allulose?

The two do different jobs, so “better” depends on the task in front of the spoon.

Stevia’s active compounds, steviol glycosides, are extracted from the leaves of a South American shrub and are hundreds of times sweeter than sugar. A pinch does the work of a teaspoon. That intensity is an advantage in beverages and a handicap in baking, where sugar supplies structure, moisture retention and browning as well as taste. Stevia contributes none of those, and many people detect a bitter or licorice-like aftertaste, particularly at higher concentrations.

Allulose behaves like sugar in almost every physical respect. It dissolves cleanly, holds moisture in cakes, forms a chewy texture in cookies and caramelizes in a pan. Its aftertaste is minimal. The price of that versatility is bulk: to match a cup of sugar’s sweetness takes roughly a cup and a third of allulose, which is also the amount most likely to provoke the digestive effects described earlier.

On safety, the files look different in shape rather than in verdict. Steviol glycosides have been reviewed by the FDA, the European Food Safety Authority and the WHO’s joint expert committee on food additives, with an established acceptable daily intake and a long history of use. Allulose has GRAS status in the US and approval in several Asian markets but no EU authorization and a shorter track record. Neither has a cardiovascular signal of the kind erythritol carries.

One practical wrinkle deserves attention. Most granulated “stevia” products sold in bags are mostly erythritol, with a small amount of stevia extract for sweetness. Someone choosing stevia specifically to avoid erythritol needs to read the ingredient list; liquid stevia drops are usually erythritol-free, while baking blends usually are not.

A reasonable rule of thumb: stevia for coffee and tea, allulose for the oven, and neither in quantities that make either the centerpiece of a day’s eating.

Common myths about allulose and erythritol, corrected

Viral claims travel faster than corrections. Here are the ones that appear most often, each set against what the evidence supports.

“Erythritol causes heart attacks.” Not established. Observational studies found an association between blood erythritol and cardiovascular events, and small volunteer studies found a platelet effect. No trial has shown that eating erythritol causes a heart attack. The data justify caution, particularly for people with existing heart disease, not a declaration of cause.

“Allulose is natural Ozempic.” False as a comparison. Rodent studies show a brief GLP-1 rise; human weight-loss data are minimal; a medication that lasts a week is not analogous to a food that nudges a hormone for minutes.

“Allulose has zero carbs.” False. It is a carbohydrate by chemistry and counts toward total carbohydrate on US labels. It is excluded from the “sugars” lines because the body does not use it for energy, which is a different statement.

“Sugar alcohols contain alcohol.” False. The term describes molecular structure, not ethanol content. Erythritol will not affect sobriety or interact with alcohol-sensitive medications through any alcohol mechanism.

“Allulose is unregulated because it’s new.” Incomplete. The FDA has reviewed multiple GRAS notices with no objection since 2012. It is unauthorized in the EU because the novel-food review process there has not concluded, not because it was rejected on safety grounds.

“Erythritol is toxic to the liver and kidneys.” Not supported. Decades of toxicology found no organ toxicity at realistic intakes. The kidney connection is about clearance, not damage.

“Any sweetener will help you lose weight.” Not supported for non-sugar sweeteners as a class. The WHO’s 2023 guideline, graded low certainty, found no long-term benefit for body weight and advised against relying on them for weight control. Sugar alcohols and allulose fell outside that review, so the honest answer for them is “untested,” not “proven.”

Who should be more careful with allulose or erythritol?

Food-level safety findings describe averages. Certain groups sit outside the average, and for them the calculation shifts.

People with established cardiovascular disease or high clotting risk. The platelet findings apply most directly here. Several cardiologists have suggested that anyone with prior heart attack, stroke, stents, atrial fibrillation or a history of clots has a reasonable case for limiting erythritol pending better data. This is expert opinion layered on mechanistic evidence, and the cardiology team should have the final word, particularly for anyone on antiplatelet or anticoagulant medicines.

People with chronic kidney disease. Both compounds depend on renal clearance and neither has been trialed in reduced kidney function. A nephrologist can weigh individual filtration rate.

People with irritable bowel syndrome or inflammatory bowel disease. Allulose’s colonic effects and, to a lesser degree, erythritol’s can worsen bloating, pain and diarrhea. Dietitians often place both on the list of ingredients to trial cautiously.

People with diabetes on glucose-lowering medicines. The sweeteners themselves do not cause low blood sugar. The risk is indirect: replacing sugar with allulose can lower post-meal readings, and interpreting those readings, or adjusting any medicine, belongs to the prescribing clinician.

Pregnant and breastfeeding women. Both are considered safe at food levels by regulators, but dedicated studies in pregnancy are lacking. Moderation and a conversation with the obstetric team are reasonable.

Children. Smaller bodies reach digestive thresholds at smaller amounts. Pediatric dietary guidance generally favors reducing overall sweetness rather than substituting one sweetener for another.

Dog owners. Xylitol, a related sugar alcohol, is severely toxic to dogs. Erythritol does not carry the same toxicity, but sugar-free products often contain more than one polyol, so keeping all of them away from pets is the simplest policy.

When to see a doctor about sweetener symptoms or heart risk

Most reactions to allulose or erythritol are mild, brief and resolve when intake drops. Some situations warrant a clinician’s attention, and a few require urgent care regardless of what caused them.

Seek emergency care immediately for any sign of a heart attack or stroke, whether or not sweeteners are suspected: chest pressure or pain lasting more than a few minutes or spreading to the arm, jaw or back; sudden shortness of breath; sudden weakness or numbness on one side of the body; facial drooping; slurred speech; sudden severe headache; or sudden vision loss. Time lost is heart or brain tissue lost.

Seek prompt care for signs of a possible blood clot in a limb, such as one calf becoming swollen, warm, red and painful, or for sudden sharp chest pain that worsens with breathing.

Book an appointment when:

• Digestive symptoms persist for more than a week after stopping allulose or erythritol, or include blood in the stool, unintended weight loss, fever or waking at night with pain. These point away from a sweetener and toward conditions that need evaluation.
• Blood glucose readings change noticeably after switching sweeteners and any medication is involved. Only the prescribing clinician should decide whether a dose needs review.
• Someone with existing heart disease, prior stroke, kidney disease or a clotting disorder wants to know whether erythritol or allulose fits their situation. That conversation should happen before the habit forms, not after.
• Hives, facial swelling, wheezing or throat tightness follow a sweetened product. True allergy to these compounds is very rare, but any reaction of that kind deserves urgent assessment because another ingredient may be responsible.

Every decision about medicines, including whether a sweetener change should alter how a medication is taken, rests with the treating clinician. An article can describe evidence; it cannot examine a patient, review a medication list or order a test. Anyone unsure whether a symptom is urgent should call their clinician or an emergency line rather than wait.

Frequently asked questions

What is the downside of allulose?

The main documented downside is digestive discomfort: bloating, gas, cramping and loose stools when intake is high, especially in liquid form or on an empty stomach. Beyond that, the concerns are about missing data rather than known harm. Commercial use spans barely a decade, the European Union has not yet authorized it, and no long-term trials exist for people with kidney disease or during pregnancy.

Which is better, stevia or allulose?

Neither is better across the board; they suit different uses. Stevia is hundreds of times sweeter than sugar and works well in drinks but adds no bulk or browning to baked goods and can taste bitter. Allulose behaves almost exactly like sugar in the kitchen but must be used in larger amounts, which raises the chance of digestive upset. Both have flat blood glucose responses.

Is allulose like Ozempic?

No. The comparison arises because allulose stimulates GLP-1 release in rodents, and semaglutide medications mimic that hormone. The natural hormone lasts minutes, the medication lasts about a week, and human trials of allulose have not demonstrated meaningful appetite suppression or weight loss. Anyone considering GLP-1 medication should discuss it with their treating clinician rather than rely on a sweetener.

Is allulose safe for kidneys?

For people with healthy kidneys, animal toxicology and short human trials show no kidney harm at food-level intakes, even though most absorbed allulose exits through the urine. The gap is in chronic kidney disease, where clearance is reduced and no trials have been done. Anyone with reduced kidney function or on dialysis should ask their nephrology team before making allulose a daily habit.

Does erythritol really cause blood clots?

It has not been shown to cause clots in people. Small volunteer studies found that erythritol made platelets more reactive to clotting triggers in laboratory tests for a day or more after a serving, and observational cohorts linked higher blood levels to cardiovascular events. Those are signals of a plausible mechanism and an association, not proof of cause. People with existing heart disease have reasonable grounds to limit it while research continues.

Does allulose raise blood sugar or insulin?

Eaten alone, allulose produces essentially no rise in blood glucose or insulin because the body cannot metabolize it. In small randomized trials, eating it alongside starchy or sugary food modestly reduced the post-meal glucose peak. These trials were short and involved fewer than 100 participants each, so long-term effects on HbA1c or diabetes complications remain untested.

Is erythritol in products labeled as stevia or monk fruit?

Frequently, yes. Because steviol glycosides and monk fruit extract are so intensely sweet, most granulated blends use erythritol as the bulking agent that makes them measure like sugar; the stevia or monk fruit may be a small fraction of the contents. Liquid drops are usually erythritol-free. The ingredient list, not the front of the package, tells the story.

Can I bake with allulose the way I bake with sugar?

Mostly. Allulose dissolves, retains moisture and caramelizes, so cakes stay tender and cookies stay chewy. It browns faster than sugar, so lowering oven temperature slightly and watching for early color helps. Because it is about 70 percent as sweet, recipes typically need a little more of it, which is also why baked goods can be the form most likely to cause digestive symptoms.

Is erythritol safe to eat every day?

Regulators worldwide consider erythritol safe at food-level intakes, and decades of toxicology support that. The open question is whether daily use over years affects cardiovascular risk, given the 2023 and 2024 platelet findings. No trial has answered it. Healthy adults using it occasionally have little reason for alarm; those with heart disease, prior stroke or clotting disorders should raise the question with their clinician.

Is allulose safe during pregnancy?

Regulatory reviews classify allulose as safe at food levels, and there is no evidence of harm, but dedicated pregnancy studies are lacking. Digestive effects such as bloating may be more bothersome when pregnancy already slows digestion. Moderation is sensible, and the obstetric team is the right place to ask about any regular dietary addition during pregnancy or breastfeeding.

References

• WHO: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline (May 2023)
• MedlinePlus: Sweeteners – sugar substitutes
• NHS: Are sweeteners safe?

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.